European Biopharmaceutical Review |
 |
|
|
|
| At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. EBR provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of of biopharmaceuticals, take a look below at the range of articles featured in this issue of EBR |
 |
| |
|
|
|
| Effective risk management reduces the likelihood that a company will suffer damaging business disruption. Prevention is better than cure, and can even be cost efficient. In Risky Business in the Globalised Economy, Tom Roche at FM Global outlines a sensible approach |
|
|
| Access to resources and finance are widely available to biopharma start-ups – it’s all about making a concept attractive to investors. Susannah Adams at Critchleys Chartered Accountants takes a lesson from history, in From Idea to Market: Four Top Tips |
|
|
| As new drugs are launched over the next decade, the salvage therapy market for HIV will become increasingly crowded, and with late-stage patients likely to decrease, it is innovation from early-stage companies that looks set to transform the market. Mansi Shah and Lisette Oversteegen at DataMonitor investigate HIV: Drug Market Dynamics |
|
|
| In Small but Perfectly Formulated, William Martineau at Freedonia Group predicts an explosion in the value of nanomedicines over the coming decade |
|
|
|
| With market growth still falling short of the standard set by the US, young European biopharmaceuticals are struggling to attract the financial backing needed to diversify. Sandrine Cailleteau at Plethora Solutions reviews the ways in which innovative partnerships are Beating the Catch-22 |
|
|
| Encouraging Synergies can help the biopharma industry meet the demand for creative innovation. Nigel Sheail at Roche tackles the challenges ahead |
|
|
| The EU’s Community Patent System is eagerly awaited by industry players who see the advantages of common IP laws. Vaibhav Sarvesh at Frost & Sullivan examines the impact of increasing ComPatibility across national borders |
|
|
| Biopharmaceutical companies are outsourcing with ever-increasing confidence. It’s a Small World, find Stephanie Finnegan and Karl Pinto of Goodwin Biotechnology, Inc |
|
|
| Bringing early-stage innovations to market has in the past, followed one of two traditional routes. Gavin Weir and Isabella Roberts at Simmons & Simmons highlight a new trend and determine its viability, in M&A and Licensing – Two Journeys, Same Destination |
|
|
|
| Capable of improving diagnosis and disease treatment, whilst speeding up drug development, one analytical approach that has been growing in popularity is assessed by Steven Fischer at Agilent Technologies, in Rising to the Challenge: Metabolomics in Disease and Drug Development |
|
|
| Small But Effective: Nanoparticles in Cancer Therapies – with their potential for imaging and drug delivery, nanocells are a versatile anti-cancer drug carrier, discovers Thomas W Rademacher of Midatech |
|
|
| One of the most exciting areas currently in development, antitumoural therapies point towards a promising future when it comes to Improving Tumour Immunity for cancer. Kostas Kosmatopoulos of Vaxon-Biotech and Jean-Pierre Abastado at the Laboratoty for Tumour Immunology, Singapore Immunology Network offer their insight |
|
|
| For successful gene optimisation, several parameters must be considered. In Pharma Research Meets Synthetic Biology, GENEART’s Marcus Graf, Thomas Schoedl, David Raab and Ralf Wagner take a holistic approach |
|
|
|
|
| Early identification maximises the benefits of new therapeutics. In Drugs in Search of Diseases, Duncan McHale and Albert B Seymour at Pfizer Global Research and Development analyse novel methodologies |
|
|
| Fragment-based drug discovery is a rapidly developing field that is being embraced by both pharmaceutical and biotech companies, find Markus Schade, Thomas Hesterkamp, John Barker and Mark Whittaker at Evotec, in Hunting Down the Drugs |
|
|
| Making Sense of biosensor technology has become a critical part of product analysis, and not just that, but quality control and stability testing as well. Maria Minunni, Sara Tombelli and Marco Mascini at the Chemistry Department, and Anna Rita Bilia at the Pharmaceutical Science Department of Florence University, provide an in-depth overview of the possibilities |
|
|
|
| Manage Risk, Manage the Regulator, argue Oliver Steck and Richard Petherick at WCI Consulting Ltd, as they evaluate methods for demonstrable public safety as well as increased private profit |
|
|
| Successful biopharmaceutical transportation comes when scientists and medical personnel work alongside transportation professionals. In Classified Information: Shipping Biological Substances, Michael Gotz at QuickSTAT leads by example |
|
|
| Tackling the difficult problem of the immune system’s reaction to certain drugs, Philippe Stas and Ignace Lasters at AlgoNomics discuss Protein Therapeutics: The Immunogenicity Risk |
|
|
|
| The need for capacities above and beyond several thousand litres is leading some companies to implement unorthodox solutions. In Bioprocess Facilities: The Disposable Revolution, Alcimed’s Rodolphe Renac, Xavier Pinardon and Xavier Revest broach the issues |
|
|
| The constant requirement for increasing yields must be met by new techniques that are both cost-effective and safe. Monica Cardona at Pall Life Sciences weighs the advantages of one such technique against the dangers, in Air Fermentation: Risks and Benefits |
|
|
| According to Frances Neville, Alexander Vakurov, Michael Broderick and Paul Millner at the Biosensors and Biocatalysis Group at the University of Leeds, nanoparticles offer Small Solutions for Greener Chemistry |
|
|
|
| With the right demographics and a sound infrastructure, Australia has begun to look increasingly attractive to foreign biotech firms – Nicola Watkinson of Invest Australia reveals The Oz Factor |
|
|
|
|
|
